Literature DB >> 18060534

Assessment of hypercoagulability markers and lipid levels in postmenopausal women undergoing either oral or transdermal hormone replacement therapy.

Daniela Amorim Melgaço Guimarães1, Maria das Graças Carvalho, Jarbas Cardoso, Marinez de Oliveira Sousa, Romerson Martins Franco, Hilton de Almeida Franco, Túlio César Alvim, George da Silva Teixeira, Luci Maria SantAna Dusse, Ana Paula Fernandes.   

Abstract

BACKGROUND: This study investigated the effect of either oral or transdermal hormone replacement therapy (HRT) on haemostatic, fibrinolytic and lipid profiles in a group of Brazilian women 3 months after beginning treatment by comparing these results with those obtained immediately before HRT.
METHODS: Plasma levels of TAT, DDi, F1+2, PC, PS, AT, PAI-1 and serum lipids were determined in blood samples collected from 24 women undergoing oral HRT and from 11 women undergoing transdermal HRT.
RESULTS: Significant increases in DDi and F1+2 plasma levels were observed after 3 months of oral HRT, while PS levels decreased. After transdermal HRT, a significant decrease was observed only for AT levels.
CONCLUSION: After 3 months of oral HRT and in the absence of major genetic and acquired risk factors, women displayed a predisposition for activation of blood coagulation, and an increased activity of the fibrinolytic system. Oral HRT seemed to be more effective in predisposing haemostatic changes as compared to transdermal.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18060534     DOI: 10.1007/s11239-007-0169-7

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  29 in total

1.  Relation of fibrinolytic potentiation by estrogen to coagulation pathway activation in postmenopausal women.

Authors:  K K Koh; M K Horne; G Csako; M A Waclawiw; R O Cannon
Journal:  Am J Cardiol       Date:  1999-02-01       Impact factor: 2.778

Review 2.  Hormone therapy to prevent disease and prolong life in postmenopausal women.

Authors:  D Grady; S M Rubin; D B Petitti; C S Fox; D Black; B Ettinger; V L Ernster; S R Cummings
Journal:  Ann Intern Med       Date:  1992-12-15       Impact factor: 25.391

Review 3.  Cardiovascular effects of oestrogens.

Authors:  J C Stevenson
Journal:  J Steroid Biochem Mol Biol       Date:  2000-11-30       Impact factor: 4.292

4.  Hormone replacement therapy with estradiol and risk of venous thromboembolism--a population-based case-control study.

Authors:  E Høibraaten; M Abdelnoor; P M Sandset
Journal:  Thromb Haemost       Date:  1999-10       Impact factor: 5.249

5.  The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal status.

Authors:  J Gilabert; A Estellés; A Cano; F España; R Barrachina; S Grancha; J Aznar; M Tortajada
Journal:  Am J Obstet Gynecol       Date:  1995-12       Impact factor: 8.661

Review 6.  Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force.

Authors:  Jill Miller; Benjamin K S Chan; Heidi D Nelson
Journal:  Ann Intern Med       Date:  2002-05-07       Impact factor: 25.391

7.  Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.

Authors:  S Vehkavaara; A Silveira; T Hakala-Ala-Pietilä; A Virkamäki; O Hovatta; A Hamsten; M R Taskinen; H Yki-Järvinen
Journal:  Thromb Haemost       Date:  2001-04       Impact factor: 5.249

8.  Effect of oral hormone replacement therapy on plasma homocysteine levels.

Authors:  Daniela Amorim Melgaço Guimarães; Jarbas Cardoso; Luci Maria Sant'ana Dusse; Romerson Martins Franco; Hilton de A Franco; Túlio César Alvim; George da Silva Teixeira; Maria das Graças Carvalho; Ana Paula Fernandes
Journal:  Acta Obstet Gynecol Scand       Date:  2006       Impact factor: 3.636

9.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.

Authors:  S Hulley; D Grady; T Bush; C Furberg; D Herrington; B Riggs; E Vittinghoff
Journal:  JAMA       Date:  1998-08-19       Impact factor: 56.272

10.  Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease.

Authors:  David M Herrington; Eric Vittinghoff; Timothy D Howard; David A Major; John Owen; David M Reboussin; Donald Bowden; Vera Bittner; Joel A Simon; Deborah Grady; Stephen B Hulley
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-06-01       Impact factor: 8.311

View more
  1 in total

1.  Risk of venous thromboembolic disease in postmenopausal women taking oral or transdermal hormone replacement therapy.

Authors:  Barbara Ruszkowska; Grażyna Gadomska; Liliana Bielis; Marzena Gruszka; Barbara Góralczyk; Danuta Rość; Grażyna Odrowąż-Sypniewska
Journal:  J Zhejiang Univ Sci B       Date:  2011-01       Impact factor: 3.066

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.